$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000162828015006379 Filed on August 10, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$75.00K	$30.00K	$0.00
YoY Change
Cost Of Revenue	$940.0K	$116.0K	$0.00
YoY Change
Gross Profit	-$865.0K	-$86.00K	$0.00
YoY Change
Gross Profit Margin	-1153.33%	-286.67%
Selling, General & Admin	$12.91M	$13.07M	$5.061M
YoY Change	82.49%	158.19%	46.7%
% of Gross Profit
Research & Development	$3.998M	$4.021M	$4.534M
YoY Change	-24.92%	-11.31%	76.01%
% of Gross Profit
Depreciation & Amortization	$300.0K	$200.0K	$100.0K
YoY Change	200.0%	100.0%	100.0%
% of Gross Profit
Operating Expenses	$17.85M	$17.20M	$9.595M
YoY Change	43.94%	79.3%	59.36%
Operating Profit	-$17.77M	-$17.17M	-$9.595M
YoY Change	43.33%	78.99%	59.36%
Interest Expense	-$180.0K	-$290.0K	-$320.0K
YoY Change	-67.27%	-9.38%	-1166.67%
% of Operating Profit
Other Income/Expense, Net	$25.00K	-$28.00K	$24.00K
YoY Change	4.17%	-216.67%
Pretax Income	-$17.92M	-$17.49M	-$9.890M
YoY Change	38.72%	76.85%	64.83%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.92M	-$17.49M	-$9.893M
YoY Change	38.68%	76.79%	64.99%
Net Earnings / Revenue	-23896.0%	-58300.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$149.30	-$145.80	-$98.90
COMMON SHARES
Basic Shares Outstanding	27.27M shares		24.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$141.7M	$155.6M	$81.40M
YoY Change	96.26%	91.15%	49.91%
Cash & Equivalents	$50.84M	$70.24M	$16.55M
Short-Term Investments	$90.80M	$85.40M	$64.80M
Other Short-Term Assets	$3.600M	$3.500M	$1.200M
YoY Change	157.14%	191.67%	33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$145.3M	$159.2M	$82.60M
YoY Change	97.45%	92.69%	49.47%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.717M	$4.208M	$1.900M
YoY Change	116.68%	121.47%	113.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$241.0K	$557.0K	$1.100M
YoY Change	-59.83%	-49.36%
Other Assets	$0.00	$0.00	$200.0K
YoY Change	-100.0%	-100.0%	127.27%
Total Long-Term Assets	$7.485M	$5.292M	$3.200M
YoY Change	91.92%	65.38%	227.2%
TOTAL ASSETS
Total Short-Term Assets	$145.3M	$159.2M	$82.60M
Total Long-Term Assets	$7.485M	$5.292M	$3.200M
Total Assets	$152.8M	$164.5M	$85.80M
YoY Change	97.17%	91.67%	52.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.156M	$2.987M	$1.400M
YoY Change	38.53%	113.36%	548.15%
Accrued Expenses	$5.700M	$4.600M	$5.600M
YoY Change	-1.72%	-17.86%	250.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.863M	$7.598M	$7.100M
YoY Change	12.08%	7.01%	291.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$358.0K	$149.0K	$100.0K
YoY Change	258.0%	49.0%	566.67%
Total Long-Term Liabilities	$358.0K	$149.0K	$100.0K
YoY Change	258.0%	49.0%	566.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.863M	$7.598M	$7.100M
Total Long-Term Liabilities	$358.0K	$149.0K	$100.0K
Total Liabilities	$10.22M	$7.747M	$7.100M
YoY Change	14.84%	9.11%	288.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$147.3M	-$129.4M
YoY Change
Common Stock	$27.00K	$27.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$142.6M	$156.7M	$78.70M
YoY Change
Total Liabilities & Shareholders Equity	$152.8M	$164.5M	$85.80M
YoY Change	97.17%	91.67%	52.56%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$17.92M	-$17.49M	-$9.893M
YoY Change	38.68%	76.79%	64.99%
Depreciation, Depletion And Amortization	$300.0K	$200.0K	$100.0K
YoY Change	200.0%	100.0%	100.0%
Cash From Operating Activities	-$12.52M	-$12.06M	-$6.570M
YoY Change	46.78%	83.56%	27.33%
INVESTING ACTIVITIES
Capital Expenditures	$1.170M	$760.0K	$1.160M
YoY Change	277.42%	-34.48%	2220.0%
Acquisitions
YoY Change
Other Investing Activities	-$5.780M	-$52.29M	-$31.84M
YoY Change	-228.16%	64.23%	225.56%
Cash From Investing Activities	-$6.950M	-$53.05M	-$33.00M
YoY Change	-265.48%	60.76%	235.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	640.0K	-20.00K
YoY Change	-188.89%	-3300.0%
NET CHANGE
Cash From Operating Activities	-12.52M	-12.06M	-6.570M
Cash From Investing Activities	-6.950M	-53.05M	-33.00M
Cash From Financing Activities	80.00K	640.0K	-20.00K
Net Change In Cash	-19.39M	-64.47M	-39.59M
YoY Change	338.69%	62.84%	163.93%
FREE CASH FLOW
Cash From Operating Activities	-$12.52M	-$12.06M	-$6.570M
Capital Expenditures	$1.170M	$760.0K	$1.160M
Free Cash Flow	-$13.69M	-$12.82M	-$7.730M
YoY Change	54.86%	65.85%	48.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27266850	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2014Q4	ovas	Availablefor Sale Securities Continuous Unrealized Loss Position Lessthan Twelve Months Numberof Securities AvailableforSaleSecuritiesContinuousUnrealizedLossPositionLessthanTwelveMonthsNumberofSecurities	32	investment
CY2015Q2	ovas	Availablefor Sale Securities Continuous Unrealized Loss Position Lessthan Twelve Months Numberof Securities AvailableforSaleSecuritiesContinuousUnrealizedLossPositionLessthanTwelveMonthsNumberofSecurities	30	investment
CY2014Q4	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	6414000	USD
CY2015Q2	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	70238000	USD
CY2014Q4	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	6414000	USD
CY2015Q2	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	70238000	USD
CY2014Q4	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	60257000	USD
CY2015Q2	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	155712000	USD
CY2014Q4	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	60231000	USD
CY2015Q2	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	155619000	USD
	ovas	Income Loss Equity Method Investment IncomeLossEquityMethodInvestment	392000	USD
	ovas	Income Loss Equity Method Investment IncomeLossEquityMethodInvestment	860000	USD
CY2015Q2	ovas	Issuerof Securities Number IssuerofSecuritiesNumber	1	issuer
CY2015Q1	ovas	Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters	345000	shares
CY2014Q1	ovas	Number Of Shares Represents Partial Exercise Of Overallotment Option Granted To Underwriters NumberOfSharesRepresentsPartialExerciseOfOverallotmentOptionGrantedToUnderwriters	518630	shares
CY2015Q2	ovas	Numberof Treatments NumberofTreatments	1	treatment
CY2015Q2	ovas	Operating Leases Improvement Allowance OperatingLeasesImprovementAllowance	1200000	USD
CY2015Q2	ovas	Operating Leases Optional Extension Term OperatingLeasesOptionalExtensionTerm	P5Y
CY2015Q2	ovas	Potential Treatments In Development PotentialTreatmentsInDevelopment	2	treatment
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	0	USD
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	1365000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2520000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2987000	USD
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7654000	USD
CY2015Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4611000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1138000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1556000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-94000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150025000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	286168000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	385000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	440000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3571000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4856000	shares
CY2015Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	25200	sqft
CY2014Q4	us-gaap	Assets Assets	65572000	USD
CY2015Q2	us-gaap	Assets Assets	164454000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	61878000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	159162000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	60231000	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	155619000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	28000	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	60257000	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	155712000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	44200000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	60200000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	2200000	USD
CY2015Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	32	investment
CY2015Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	2	investment
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18078000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16553000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6414000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70238000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24413666	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27263100	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24084637	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27263100	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9888000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17715000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17583000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34764000	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	116000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	151000	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148000	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	410000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.83
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2014Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2015Q2	us-gaap	Equity Method Investments EquityMethodInvestments	557000	USD
CY2014Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-295000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-392000	USD
CY2015Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-389000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-860000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1234000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	388000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1534000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2778000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	597000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1787000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	109000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	439000	USD
CY2014Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-27000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-84000	USD
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	101000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	145000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	10247000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	7747000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65572000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	164454000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10174000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7598000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1525000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	63824000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51639000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125428000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41635000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35159000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11529000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26445000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-9893000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17707000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-17490000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-34696000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	9595000	USD
	us-gaap	Operating Expenses OperatingExpenses	17245000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	17204000	USD
	us-gaap	Operating Expenses OperatingExpenses	34032000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4415000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1157000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9595000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17245000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17174000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33987000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1000000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	900000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	900000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	900000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	100000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-93000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-68000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	149000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1148000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	57604000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	68918000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1647000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3434000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51700000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124100000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51639000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124063000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	14320000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	33729000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3117000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4505000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5764000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3367000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4208000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4534000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9186000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4021000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9768000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	109000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	197000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	527000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94698000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129394000	USD
CY2014Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2015Q2	us-gaap	Revenues Revenues	30000	USD
	us-gaap	Revenues Revenues	45000	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	400000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5061000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8059000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13067000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24113000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3082000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10718000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
CY2015Q1	us-gaap	Share Price SharePrice	10.00
CY2015Q1	us-gaap	Share Price SharePrice	50
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	53817000	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	85381000	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5518630	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2645000	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	55325000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	156707000	USD
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23546000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21392000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27198000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26894000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles, which require management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-15-006379-index-headers.html	Edgar Link	pending
0001628280-15-006379-index.html	Edgar Link	pending
0001628280-15-006379.txt	Edgar Link	pending
0001628280-15-006379-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20150630.xml	Edgar Link	completed
ovas-20150630.xsd	Edgar Link	pending
ovas-20150630x10q.htm	Edgar Link	pending
ovas-20150630xex101.htm	Edgar Link	pending
ovas-20150630xex311.htm	Edgar Link	pending
ovas-20150630xex312.htm	Edgar Link	pending
ovas-20150630xex321.htm	Edgar Link	pending
ovas-20150630xex322.htm	Edgar Link	pending
ovas-20150630_cal.xml	Edgar Link	unprocessable
ovas-20150630_def.xml	Edgar Link	unprocessable
ovas-20150630_lab.xml	Edgar Link	unprocessable
ovas-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2015 Q3 Form 10-Q Financial Statement

#000162828015006379 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2015 Q3 Form 10-Q Financial Statement

#000162828015006379 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst